FISHERS (Inside INdiana Business) — A third life sciences company has announced plans to build a laboratory and manufacturing plant in the Fishers Life Science & Innovation Park. List Biotherapeutics Inc. says it will invest more than $125 million to establish a 110,000 square foot contract manufacturing facility and hire 210 employees by the end of 2023.
List Bio follows in the path of life sciences firms Stevanato Group and INCOG Pharma to place facilities in the business park.
The company, whose parent is South Korea-based Genome & Co., specializes in biologics manufacturing. The facility would produce microbiomes, a beneficial bacteria used to target a variety of diseases or conditions.
“Our objective with the investment for this new facility is to manufacture live biotherapeutic products for Phase 3 clinical trials and for commercial use,” said Jonathan Yongwan Jo, president and chief executive officer of List Biotherapeutics. “With that investment, we aim to become the market leader… as we harness bacterial science to help our customers create a healthier world.”
The company says the facility will offer an end-to-end manufacturing solution from early-stage development to late-stage clinical trials and commercialization in the pharmaceutical space.
“This is a tremendous development for Indiana’s life sciences sector, the City of Fishers, and the State,” said Brian Stemme, senior vice president of engagement for BioCrossroads, an initiative focused on growing the state’s life sciences industry. “It’s a testament to our experienced workforce and strength in pharmaceutical manufacturing that this global player is investing in our region.”
Pending approval of the Indiana Economic Development Corp. board of directors, based on the company’s creation plans, the IEDC will commit an investment in List Biotherapeutics Inc. of up to $3.15 million in the form of incentive-based tax credits.
The Fishers City Council is also expected to vote on additional incentives.